2023-01-16

Unconventional treatment of Autoimmune Hepatitis

In order to assess the usage of “unconventional treatment” for autoimmune hepatitis (AIH) in our ERN community, we would like to perform an online survey to collect the experiences with these new treatments in our patients. We define “unconventional treatment” as new agents that have not been defined as 2nd or 3rd line treatment for AIH in the past and are used more in the fields of dermatology, rheumatology or inflammatory bowel disease.

in order to assess the usage of “unconventional treatment” for autoimmune hepatitis (AIH) in our ERN community, we would like to perform an online survey to collect the experiences with these new treatments in our patients. We define “unconventional treatment” as new agents that have not been defined as 2nd or 3rd line treatment for AIH in the past and are used more in the fields of dermatology, rheumatology or inflammatory bowel disease. To give an example, we would define abatacept or tofacitinib as “unconventional treatments”.

We define the following agents as 2nd- or 3rd line treatment of AIH and cases treated with these agents will NOT be collected by this survey: mercaptopurine, thioguanine, MMF, tacrolimus, everolimus, cyclosporine, cyclophosphamid, rituximab or anti-TNF.

If you have experience with a single or several cases under “unconventional treatment”, please complete our survey by following this link:

https://ec.europa.eu/eusurvey/runner/unconventional_treatment_of_AIH

Even if you have not yet treated AIH patients with such agents, please provide this information in the survey.

All centres contributing at least one case will receive a co-authorship in a future publication (one co-author per contributing centre).

The survey will be open until 19 February 2023.

We are looking forward to collecting these cases and sharing the experiences with these agents with you.